IP Library › Granted Patent US 11,052,063
Granted Patent B2
US 11,052,063 · App. 16/713,461 · Granted Jul 6, 2021

Methods of reducing RLP-C

Inventors: Ian Osterloh (Kent, GB); Pierre Wicker (Mystic, CT); Rene Braeckman (Richboro, PA); Paresh Soni (Mystic, CT); Mehar Manku (Birmingham, GB)
Assignee: Amarin Pharmaceuticals Ireland Limited
A61K31/232A61K31/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,052,063
App. No.
16/713,461
Granted
Jul 6, 2021
Kind
B2
Abstract

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.

Claims (10)

1. A method of reducing an RLP-C level of a subject on statin therapy, having a baseline RLP-C level of about 10 mg/dl to about 20 mg/dl, and having baseline fasting triglycerides of about 200 mg/dl to 499 mg/dl, the method comprising administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of ethyl eicosapentaenoate per day.

2. The method of claim 1 , wherein the RLP-C level is reduced by at least about 15%.

3. The method of claim 1 , wherein the RLP-C level is reduced by at least about 20%.

4. The method of claim 1 , wherein about 2 g per day of ethyl eicosapentaenoate is administered to the subject.

5. The method of claim 1 , wherein about 3.8 g to about 4 g per day of ethyl eicosapentaenoate is administered to the subject.

6. The method of claim 1 , wherein the pharmaceutical composition is administered to the subject daily for a period of 1 to about 12 weeks.

7. The method of claim 1 , wherein the reduction in RLP-C level is in comparison to control subjects on statin therapy, having baseline RLP-C levels of about 10 mg/dl to about 20 mg/dl, and having baseline fasting triglycerides of about 200 mg/dl to 499 mg/dl who have received the statin but not the pharmaceutical composition.

8. The method of claim 1 , wherein the pharmaceutical composition comprises at least about 95%, by weight of all fatty acids present, ethyl eicosapentaenoate.

9. The method of claim 1 , wherein the pharmaceutical composition comprises no more than about 10%, by weight of all fatty acids present, docosahexaenoic acid or a derivative thereof, if any.

10. The method of claim 1 , wherein the pharmaceutical composition comprises at least about 95%, by weight of all fatty acids present, ethyl eicosapentaenoate and no more than about 2%, by weight of all fatty acids present, docosahexaenoic acid or a derivative thereof, if any.